Annamycin treats soft tissue sarcoma, has been awarded FDA 'orphan drug title'

Sarcoma is a rare heterogeneic malignancy from a type of interstity cell source, accounting for less than 1% of all adult malignancies and 12% of pediatric cancers.
about 80% of new sarcoma comes from soft tissue and the rest from bone.
Drug Enforcement Administration (FDA) has awarded Annamycin the "Orphan Drug Title" (ODD) for the treatment of soft tissue sarcoma, the pharmaceutical company Moleculin Biotech announced today.
FDA recently allowed Moleculin to conduct phase IB/II clinical trials in the United States for patients with soft tissue sarcoma (STS) who have metasized to the lungs.
the clinical trial includes recent animal data and data presented at the 2020 annual meeting of the American Association for Cancer Research (AACR).
data show that Annamycin's lung build-up levels are six to 34 times higher than those of amycin, the main first-line chemotherapy drug for soft tissue sarcoma.
, clinical data show that Annamycin is not heart toxic and can avoid multiple drug resistance.
, Annamycin may represent an important treatment. Walter Klemp, chairman and chief executive officer of
Moleculin, commented: "This is Annamycin's second "orphan drug title", which has previously been awarded as an orphan drug for the treatment of recurring or resuscable acute myeloid leukemia."
。